WRF Capital

What WRF Capital does

WRF Capital is the dedicated venture investment vehicle of the Washington Research Foundation (WRF), a private, independent nonprofit foundation established in 1981 by Tom Cable, Bill Gates Sr., and Hunter Simpson to operationalize the Bayh-Dole Act for Washington state's research institutions. WRF Capital invests approximately $5 million per year in early-stage startups spun out of the University of Washington, Washington State University, Fred Hutchinson Cancer Research Center, the Institute for Systems Biology, Seattle Children's Research Institute, the Allen Institute for AI, and other Washington state nonprofit research institutions, often leading or syndicating the first institutional round. The portfolio spans life sciences (biotechnology, pharmaceuticals, medical devices, digital health) and enabling technologies (advanced materials, scientific instrumentation, AI), and includes companies such as Sana Biotechnology (valued at $6B+ shortly after its 2021 IPO), A-Alpha Bio, Outpace Bio, Monod Bio, Xaira Therapeutics, and mpathic.

The organization's broader operating model extends well beyond pure venture investing into an integrated stack of grant and talent programs. WRF administers phased Technology Commercialization Grants (up to $1M in direct costs across three phases), three-year Postdoctoral Fellowships, Student Programs at Washington colleges and universities, and large-scale BioInnovation Grants — most recently committing $32M+ to four flagship initiatives including the Seattle Hub for Synthetic Biology. Since 1993, WRF has disbursed more than $190 million in grants, and its licensing program has returned more than $445 million to research institutions including the University of Washington, anchored by landmark patents such as the yeast expression technology licensed to Genentech that underpins manufacturing of insulin and Merck's Gardasil vaccine.

WRF Capital is supported by a 12-person team led by President & CEO Orin Levine, Ph.D. (former Gates Foundation senior director and Johns Hopkins professor) and CFO Morgan Hellar, with senior investment professionals holding cross-disciplinary credentials in AI/ML, bioengineering, and health economics. The foundation is self-funded through an endowment generated by its licensing program and reinvested into both grants and venture investments; it has no external LPs or parent company, and operates from a Seattle headquarters that includes a 15,000-square-foot WRF Venture Center subleased to portfolio companies. The combination of patient, endowment-derived capital, multi-decade institutional relationships, and an integrated grant-plus-venture model positions WRF Capital as a structurally unique "first money in" investor in Washington state's research-driven startup pipeline.

Name

WRF Capital

Legal name

Washington Research Foundation

Website

https://wrfseattle.org

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

1–10 employees

Short description

WRF Capital is the venture investment arm of the Washington Research Foundation, deploying roughly $5M annually into early-stage startups spun out of Washington state research institutions across life sciences, enabling technologies, and AI. It operates an integrated model combining venture investing with phased commercialization grants, postdoctoral fellowships, and large-scale BioInnovation initiatives.

Ownership category

akta.pro rank

Product category

Venture Capital and Research Foundation Grant Programs

NAICS

Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital investing
• Technology commercialization grants
• Postdoctoral fellowship funding
• University technology licensing
• Early-stage startup investments

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others, Marketing or Sales

Revenue model

1. Investment Returns (Portfolio Exit): WRF Capital generates returns through successful portfolio company exits including IPOs and acquisitions. These returns are reinvested into additional local startups and to support grantmaking activities.
2. Licensing Revenue: WRF earned more than $445 million for the University of Washington and other nonprofit research institutions through its licensing program, returning proceeds to originating institutions to fund additional research and scholarship.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

WRF Capital is the early-stage venture capital investment vehicle of Washington Research Foundation, investing approximately $5 million annually in Washington state startup companies spun out from nonprofit research institutions. The foundation complements these investments with technology commercialization grants, postdoctoral fellowships, student program funding, and large-scale BioInnovation Grants to bridge the gap between discovery research and commercial investment in life sciences and enabling technologies.

Product overview

WRF Capital is the investment vehicle for Washington Research Foundation, a private foundation supporting groundbreaking research and early-stage companies in Washington state since 1981. The organization operates through its core WRF Capital Investment Program for venture investments in startups, complemented by grant programs including Technology Commercialization Grants, WRF Postdoctoral Fellowships, Student Programs, and BioInnovation Grants. Together these programs support the development of innovations in life sciences and enabling technologies from Washington state research institutions. The organization has invested in more than 130 local startups since 1996, earned over $445 million for research institutions through licensing, and provided over $190 million in grants.

Differentiator

Problem solved

Functional benefit

Products and services

• WRF Capital Investment Program Early-stage venture capital investments in startup companies based in Washington state, with a focus on spinouts from nonprofit research institutions including UW, WSU, Fred Hutch, ISB, and Seattle Children's. The program invests approximately $5 million annually.
• Technology Commercialization Grants Project-based funding supporting the commercial development of technology-based products from Washington state research institutions, with phased funding up to $1 million through pre-proposal, Phase 1 ($10K-$100K), Phase 2 (up to $250K), and Phase 3 (up to $1M) stages.
• WRF Postdoctoral Fellowships Three-year salary support for outstanding postdoctoral scientists conducting innovative, translational research at Washington state research institutions, including $15,000 for research supplies, equipment, and/or travel.
• Student Programs Funding for student programs at Washington state colleges and universities related to STEM research and entrepreneurship, including undergraduate research fellowships, ARCS graduate scholars, and innovation training fellowships.
• BioInnovation Grants Large-scale strategic funding for emergent opportunities to advance Washington state's life sciences ecosystem, including support for Seattle Hub for Synthetic Biology, WSU's Soil to Society initiative, Fred Hutch-Seattle Children's Bridging the Clinical Gap collaboration, and UW Institute for Protein Design's De Novo Design of Catalytic Enzymes initiative.
• WRF Venture Analyst Program Part-time opportunity for graduate students and postdoctoral fellows to conduct due diligence on grant and investment opportunities in life sciences and enabling technologies, working up to 10 hours per week at $35/hour.

Quantifiable outcome

• 130+ startups funded since 1996 with successful exits including IPOs and acquisitions
• +3 more outcomes

Named customers10 records

Segments2 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eleven partnerships are on record, tiered core, major, minor and flagship.

• University of WashingtoncoreStrategic or Co-development PartnerPrimary source of technology spinouts; UW is the largest nonprofit research institution in Washington state with leading programs in life sciences, engineering, and technology.
• Washington State UniversitycoreStrategic or Co-development PartnerMajor research university in Washington state and source of technology spinouts; WRF supports WSU commercialization gap fund and collaborative programs.
• Fred Hutchinson Cancer Research CentercoreStrategic or Co-development PartnerLeading cancer research center in Seattle; source of numerous biotech spinouts; WRF supports Bridging the Clinical Gap collaboration and IND-Enabling programs.
• Seattle Children's Research InstitutecoreStrategic or Co-development PartnerSource of pediatric healthcare and biotech innovations; WRF provided $12.5M to Invent at Seattle Children's Postdoctoral Scholars Program.
• Institute for Systems Biology (ISB)coreStrategic or Co-development PartnerPioneering systems biology research institute; source of biotech spinouts; WRF supports ISB Innovator Award Program.
• Allen Institute for AIcoreStrategic or Co-development PartnerAI research institute; source of AI-focused technology spinouts including Birch.AI.
• Creative Destruction Lab (CDL-Seattle)majorStrategic or Co-development PartnerGlobal startup program for seed-stage, science-based companies located at UW Foster School of Business; benefits from partnerships with Microsoft, WRF, The Foster Foundation, and Allen Institute for AI.
• MicrosoftminorGTM or Marketing PartnerCorporate partner supporting Creative Destruction Lab-Seattle; represents industry collaboration with academic ecosystem.
• Seattle Hub for Synthetic BiologyflagshipStrategic or Co-development Partner$32+ million pledged through BioInnovation Grants; SeaBridge fellowship program; major initiative to advance cell and genome technologies in Washington state.
• ARCS Foundation Seattle ChapterminorGTM or Marketing PartnerAdvancing science in America by funding PhD fellowships for outstanding STEM scholars at UW and WSU; WRF provides annual sponsorship.
• Benaroya Research InstitutecoreStrategic or Co-development PartnerAutoimmune disease research institute; source of biotech innovations; recipient of WRF Postdoctoral Fellowship and technology commercialization grants.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ARCH Venture Partners: ARCH is a long-running early-stage venture firm that builds and invests in life sciences and technology companies, frequently out of academic research institutions. Like WRF Capital, ARCH is often the first capital into deep-tech spinouts, making it the closest direct comparability for WRF's research-spinout investment model.
• Madrona Venture Group: Madrona is the Pacific Northwest's leading early-stage venture firm, headquartered in Seattle and focused on early-stage tech and life sciences companies emerging from regional institutions. WRF Capital shares Madrona's regional concentration and early-stage emphasis, making it a natural operating peer in the same geography.
• Pioneer Square Labs: PSL is a Seattle-based early-stage venture firm that builds technology startups and invests in spinouts from the Pacific Northwest innovation ecosystem. Like WRF Capital, it operates at the earliest stage and closely with regional research institutions, including partnerships at UW.
• The Column Group: The Column Group is an early-stage venture firm that partners with leading academic scientists to found and fund biotech companies. Its model of seeding companies directly out of academic labs makes it a close functional peer to WRF Capital's life sciences investment program at research institutions.
• Atlas Venture: Atlas Venture builds and invests in early-stage biotech companies, often around breakthrough academic science, with a focus on forming new companies. Its emphasis on company formation in therapeutics and platform biology is structurally similar to WRF Capital's spinout-focused life sciences investing.
• Versant Ventures: Versant Ventures is a healthcare-focused venture firm that builds and invests in biotech and medtech companies, often in early-stage syndicates. WRF Capital's biotech and medical device investments at Seattle research institutions overlap meaningfully with Versant's investment categories.

Broad incumbents

• Alexandria Real Estate Equities / Alexandria Venture Investments: Alexandria is a large, established life sciences landlord and venture investor operating broadly across the biotech industry. WRF Capital sits adjacent as a much smaller, regionally focused investor; Alexandria is a broader incumbent for comparison purposes in life sciences venture.
• Y Combinator: Y Combinator is a leading early-stage accelerator that funds and supports startups across industries. While YC is far broader than WRF Capital, both serve as early institutional capital for nascent technology companies and share a program-driven model of providing capital plus operational support at the earliest stages.

Emerging players

• UM Ventures (University of Maryland): UM Ventures is the university-affiliated venture arm that commercializes inventions from University of Maryland research institutions. As a fellow research-institution-affiliated investment vehicle, UM Ventures offers a direct structural analog to WRF Capital's spinout investment model.

Others

• Washington State Department of Commerce (Office of Economic Development): The Washington State Department of Commerce supports innovation ecosystem development through state funding, grants, and ecosystem-building programs in Washington. WRF Capital operates within a broader ecosystem that includes these state-level efforts; the relationship is thematic rather than directly competitive.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/washington-research-foundation
• Xx.com/wrfseattle

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WRF Capital